MYMD PHARMACEUTICALS INC has a total of 33 patent applications. It increased the IP activity by 42.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are NUEVAS ALTERNATIVAS NATURALES S A P I DE C V, ALLOCYTE PHARMACEUTICALS AG and KENNETH S WARREN INST INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 17 | |
#2 | Canada | 4 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Australia | 2 | |
#5 | Republic of Korea | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | China | 1 | |
#8 | Germany | 1 | |
#9 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Organic fine chemistry | |
#5 | Foods and drinks | |
#6 | Medical technology | |
#7 | Consumer goods |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Peptides | |
#5 | Specific use of cosmetics | |
#6 | Microorganisms | |
#7 | New plants | |
#8 | Tobacco | |
#9 | Heterocyclic compounds | |
#10 | Syringes |
# | Name | Total Patents |
---|---|---|
#1 | Williams Jonnie R | 32 |
Publication | Filing date | Title |
---|---|---|
US2020338061A1 | Methods of Regulating Oxidoreductase Activity for Treatment of Inflammation and Age-Related Disorders | |
CA3026911A1 | Genetically modified tobacco | |
KR20200061384A | How to reverse normal aging process and prolong life | |
US2018140590A1 | Method of treating addictions to opioids | |
US2017333415A1 | Method of treating substance addictions | |
CA3013634A1 | Methods of increasing hair growth and improving hair appearance | |
CA2980030A1 | Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation | |
US2018271875A1 | Alkaloid compounds for treating depression, substance addictions, and indications associated with chronic inflammation |